Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00838448
Other study ID # 081302
Secondary ID
Status Completed
Phase N/A
First received January 23, 2009
Last updated June 11, 2013
Start date January 2009
Est. completion date June 2013

Study information

Verified date June 2013
Source Vanderbilt University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

In this study the investigators will explore the relationship between physical activity and cannabis use. The investigators will compare regional brain activation detected by imaging technique(fRMI) before and after exercise in cannabis users and compare results with results from controls. The investigators hypothesize that the regional brain activation in response to visual cues (pictures related to cannabis use and food) will be different in cannabis users than in controls and that exercise will significantly alter brain responses to the cues.


Description:

It is unknown how the response of cannabis users might compare to those of non-users in response to similar dose of physical activity. We will therefore compare brain activation during craving to cannabis, a natural reward (food) and a neutral scene (nature images). The food cues will allow us to determine if effects of exercise on brain activation and craving generalize to two different reward conditions and the nature scenes provide a neutral, no rewarding control. In addition to the analysis of predetermined regions of interest, whole-brain exploratory analyses will also be conducted to examine for additional brain regions showing associations between various conditions of interest and regional brain activation.

Specific Aims

1. To explore methodological factors involved in finding the relationship between PA and cannabis use.

1. to examine the effects of cannabis and food cues on brain activation and craving in cannabis users and nonusers

2. to examine the effects of vigorous exercise on brain activation and craving in response to cannabis and food cues.

Our working hypothesis is that the regional brain activation in response to drug cues will be different in cannabis users than in controls and that exercise will significantly alter brain responses to these cues in both groups. Our secondary hypothesis is that exercise will tend to normalize the abnormal brain activation observed in cannabis users.

Our expectation is that exercise will alter cue-responding in terms of brain activation or craving. It is possible that exercise may be a useful treatment in cannabis dependence. Future studies may examine this specific relationship.

There are no reports available exploring the relationship between physical activity and cannabis use.

Current data suggest that there are convergent findings regarding the chronic and acute effects of cannabis on brain activity


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 2013
Est. primary completion date January 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- Cases and Controls must:

- Be able to understand the study and provide written informed consent.

- Be male or female 18 -35 years of age.

- Be in generally good health

- If female of childbearing potential, have a negative serum pregnancy test on study day

Cases must:

- Meet criteria for cannabis dependence as primary diagnosis as determined by the Substance Abuse module of SCID (Structured Clinical Interview for DSM-IV).

- Not currently seeking treatment for cannabis dependence.

- Have a positive urine drug test for cannabis on the study day

- Avoid alcohol and other recreational drug use (except cannabis and/or nicotine) for 48 h before testing.

Exclusion Criteria:

- Cases and Controls must not:

- Be pregnant or lactating

- Have implanted electrical medical device (e.g. pacemaker, vagal nerve stimulator)

- Have non-secure metallic foreign bodies

- Have met criteria for another axis 1 diagnosis in the past 6 months

- Receive psychotropically active or vasoactive medications (within 6 weeks of screen day)

- Have chronic medical illness

- Have epilepsy

- Have a history of head injury that required hospitalization

- Have claustrophobia

- Have orthopedic or other problems precluding them from performing exercise protocol

- Have body mass index (BMI) less than 19 kg/m2

- Weighing more than 275 pounds (MRI table limit)

Cases must not:

- Have current dependence, as determined by the SCID, on any psychoactive substance other than nicotine and/or cannabinoid

- Have any serious medical or psychiatric illnesses and/or clinically significant symptoms, which in the judgment of the PI or his/her designee would make them unsafe, or would make compliance with the study protocol difficult or put the study staff at undue risk

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise
Exercise performed on a treadmill for 20-30 minutes

Locations

Country Name City State
United States Vanderbilt University Medical Center Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Vanderbilt University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Craving for cannabis 1 hour No
See also
  Status Clinical Trial Phase
Completed NCT01005810 - A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana Phase 2
Completed NCT00114439 - Lithium Cannabis Withdrawal Study Phase 2
Completed NCT00350285 - The Teen Marijuana Check-Up Phase 2
Completed NCT01618656 - Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal Phase 2
Completed NCT01153490 - Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Phase 4
Completed NCT02946489 - Facilitating the Behavioral Treatment of Cannabis Use Disorder Phase 1
Completed NCT02088177 - Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence Phase 1/Phase 2
Not yet recruiting NCT01565174 - The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis N/A
Completed NCT01697709 - Quetiapine Pharmacotherapy for Cannabis Dependence Phase 2
Recruiting NCT04721353 - Reducing Cannabis Overuse With Prazosin Phase 4
Completed NCT01603992 - Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
Completed NCT00167297 - Atomoxetine for the Treatment of Cannabis Dependence Phase 2
Terminated NCT01598896 - Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Phase 2/Phase 3
Completed NCT01611948 - Treatment for Cannabis Withdrawal and Dependence Phase 2
Recruiting NCT03221231 - N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms Phase 4
Not yet recruiting NCT03366909 - Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness N/A
Completed NCT01639872 - Clozapine for Cannabis Use in Schizophrenia Phase 4
Not yet recruiting NCT06334016 - Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream Early Phase 1
Completed NCT01793961 - Effects of Chronic Intake of Cannabis on Contrast Sensitivity N/A
Completed NCT01747850 - Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence Phase 2